Sensei Biotherapeutics, Inc. 8-K/A

What Happened
Sensei Biotherapeutics, Inc. (SNSE) filed an amendment to its prior Form 8-K on April 15, 2026 (Item 9.01) to include the audited consolidated financial statements of its Faeth Subsidiary (formerly Faeth Therapeutics, Inc., a Delaware corporation) as of and for the years ended December 31, 2025 and 2024. The amendment also updates related information and exhibits previously omitted from the original report.

Key Details

• Filing date: April 15, 2026 (amendment to prior Form 8-K).
• Item affected: 9.01 — Financial Statements and Exhibits.
• Documents added: Audited consolidated financial statements of Faeth Subsidiary for the years ended December 31, 2025 and 2024.
• Subsidiary name: Faeth Subsidiary (formerly Faeth Therapeutics, Inc.), a Delaware corporation.

Why It Matters
Adding audited financial statements for the Faeth Subsidiary improves transparency and SEC compliance by providing third‑party‑audited results for that entity. Retail investors should review the newly filed audited statements and updated exhibits to understand any impact on Sensei’s consolidated financial position and disclosures. This amendment does not, by itself, report operating results or other changes beyond the inclusion of the audited financials and exhibit updates.